Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
2.32
Dollar change
-0.16
Percentage change
-6.45
%
Index- P/E- EPS (ttm)-3.64 Insider Own14.49% Shs Outstand16.39M Perf Week-18.31%
Market Cap35.32M Forward P/E- EPS next Y-2.50 Insider Trans0.00% Shs Float13.02M Perf Month-36.61%
Income-75.80M PEG- EPS next Q-0.73 Inst Own18.67% Short Float7.79% Perf Quarter-38.30%
Sales0.95M P/S37.18 EPS this Y45.42% Inst Trans9.06% Short Ratio8.49 Perf Half Y-63.23%
Book/sh1.17 P/B1.98 EPS next Y38.93% ROA-88.07% Short Interest1.01M Perf Year-47.39%
Cash/sh1.77 P/C1.31 EPS next 5Y- ROE-151.46% 52W Range2.37 - 8.95 Perf YTD-62.88%
Dividend Est.- P/FCF- EPS past 5Y-15.09% ROI-293.01% 52W High-74.08% Beta2.06
Dividend TTM- Quick Ratio1.93 Sales past 5Y-4.04% Gross Margin- 52W Low-2.11% ATR (14)0.28
Dividend Ex-Date- Current Ratio1.93 EPS Y/Y TTM-325.89% Oper. Margin-8450.79% RSI (14)27.35 Volatility12.02% 10.01%
Employees78 Debt/Eq0.75 Sales Y/Y TTM-95.23% Profit Margin-7992.60% Recom1.33 Target Price16.78
Option/ShortYes / Yes LT Debt/Eq0.35 EPS Q/Q-482.30% Payout- Rel Volume15.31 Prev Close2.48
Sales Surprise-90.21% EPS Surprise3.59% Sales Q/Q-92.02% EarningsNov 14 BMO Avg Volume119.41K Price2.32
SMA20-25.04% SMA50-27.85% SMA200-50.05% Trades Volume1,828,044 Change-6.45%
Date Action Analyst Rating Change Price Target Change
Dec-12-22Initiated H.C. Wainwright Buy $6
Oct-10-22Downgrade Stifel Buy → Hold $9 → $2
Aug-18-22Resumed Wells Fargo Overweight
Mar-31-22Initiated Piper Sandler Overweight $7
Feb-23-22Initiated Cantor Fitzgerald Overweight $12
Oct-21-21Initiated Truist Buy $10
Sep-30-21Initiated Stifel Buy $12
Mar-31-21Initiated Credit Suisse Outperform $15
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Dec-05-24 06:30AM
Nov-19-24 06:33PM
Nov-15-24 02:10AM
Nov-14-24 06:38AM
06:30AM
06:30AM Loading…
Nov-06-24 06:30AM
Nov-05-24 09:00AM
Oct-24-24 05:01PM
Oct-16-24 02:00AM
Sep-10-24 06:30AM
Sep-05-24 06:46AM
06:30AM
Sep-04-24 09:06AM
Sep-03-24 07:45AM
Aug-29-24 06:30AM
09:48AM Loading…
Jul-29-24 09:48AM
Jun-14-24 05:34PM
Jun-13-24 08:02AM
Jun-12-24 10:52AM
06:41AM
06:30AM
Jun-05-24 06:30AM
Jun-04-24 11:32AM
09:40AM
Jun-03-24 04:13PM
Jun-01-24 01:02PM
May-29-24 06:30AM
May-28-24 06:30AM
06:10AM
May-23-24 05:05PM
03:55PM Loading…
May-17-24 03:55PM
May-14-24 10:05AM
Apr-24-24 09:55AM
04:05AM
Apr-17-24 09:55AM
Apr-04-24 09:55AM
Apr-01-24 11:38AM
Mar-28-24 06:30AM
Mar-21-24 06:30AM
Mar-14-24 12:00PM
Mar-06-24 03:36PM
06:30AM
Jan-08-24 04:05PM
08:00AM
Jan-03-24 06:30AM
Dec-19-23 09:08AM
Dec-11-23 06:02AM
06:00AM
03:18AM
Dec-04-23 06:30AM
Nov-20-23 08:51AM
Nov-14-23 06:38AM
06:30AM
Nov-09-23 06:30AM
Nov-07-23 06:30AM
Nov-03-23 12:05PM
Nov-02-23 09:05AM
Nov-01-23 06:30AM
Oct-31-23 07:12PM
Oct-25-23 09:35AM
Oct-04-23 06:30AM
Sep-27-23 09:05AM
Sep-21-23 06:30AM
Sep-12-23 06:30AM
Sep-07-23 06:30AM
Aug-23-23 12:11PM
06:00AM
Aug-22-23 05:00AM
Aug-10-23 07:50AM
06:42AM
06:30AM
Aug-09-23 06:02AM
Aug-04-23 04:51PM
Aug-03-23 06:30AM
Jul-31-23 05:05PM
Jun-22-23 06:30AM
Jun-09-23 05:59PM
Jun-06-23 07:51AM
Jun-03-23 09:00AM
May-30-23 06:30AM
May-25-23 05:00PM
May-23-23 07:45AM
06:37AM
06:30AM
06:15AM
May-22-23 06:30AM
May-16-23 06:30AM
May-11-23 10:05AM
May-05-23 06:14AM
Apr-26-23 10:00AM
Apr-17-23 04:05PM
Apr-16-23 03:00PM
Apr-06-23 04:05PM
Mar-30-23 08:19AM
Mar-29-23 06:30AM
Mar-27-23 06:21AM
Mar-23-23 07:45AM
06:30AM
Mar-16-23 06:30AM
Mar-14-23 04:30PM
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.